CASTOR3

Across TCGA pan-cancer cohorts, CASTOR3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CASTOR3 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher CASTOR3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASTOR3 expression acts as an unfavorable survival marker, although some lineages such as BRCA show a favorable association.

KIRP, LUAD, and UCEC are the cancer types where CASTOR3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.141	0.772	<.001	28	view →
LUAD	DFS	Median	All	0.411	0.793	<.001	22	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	All	0.164	0.704	.025	6	view →
BRCA	OS	Median	All	0.927	0.924	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CASTOR3–KIRP (OS)

Open the KIRP breakdown →